Clover Health legal chief sells 51,700 shares

Accepted by SEC EDGAR 07/20/2026 - 05:48 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026, reported as a sale in the open market or a private transaction at a $4.51 weighted average price, with individual prices from $4.46 to $4.59, pursuant to a 10b5-1 plan adopted on March 13, 2026. Following this sale, she directly holds 1,505,522 shares.

Insider Trade Summary 10b5-1

Net Seller: 51,700 shares

Net Sell 1 txn

Insider Soares Karen

Role Chief Legal Officer

Sold 51,700 shs ($233K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	51,700	$4.51	$233K

Holdings After Transaction: Class A Common Stock — 1,505,522 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Key Figures

Shares sold: 51,700 shares Weighted average sale price: $4.51 per share Sale price range: $4.46 to $4.59 per share +1 more

4 metrics

Shares sold 51,700 shares Class A Common Stock sold on July 20, 2026

Weighted average sale price $4.51 per share Average price for the 51,700 shares sold

Sale price range $4.46 to $4.59 per share Range of prices for multiple sale transactions

Shares held after transaction 1,505,522 shares Direct ownership following the July 20, 2026 sale

Key Terms

10b5-1 plan, weighted average price, Class A Common Stock

3 terms

10b5-1 plan regulatory

"The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average price financial

"The price reported in column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CLOV report for Karen Soares?

Clover Health Investments, Corp. reported that Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026. The transaction was reported as a sale in the open market or a private transaction under a pre-arranged 10b5-1 plan adopted on March 13, 2026.

At what prices did Karen Soares sell CLOV Class A Common Stock?

Karen Soares’ sale of CLOV Class A Common Stock had a $4.51 weighted average price per share. According to the disclosure, the shares were sold in multiple transactions at prices ranging from $4.46 to $4.59 per share, inclusive, on July 20, 2026.

How many CLOV shares does Karen Soares hold after this Form 4 sale?

After the reported sale, Karen Soares directly holds 1,505,522 shares of Clover Health Class A Common Stock. This figure reflects her direct ownership position immediately following the July 20, 2026 sale of 51,700 shares reported in the Form 4 filing.

Was the CLOV insider sale by Karen Soares under a 10b5-1 plan?

Yes, the sales reported for CLOV by Karen Soares were effected pursuant to a 10b5-1 plan. The filing states that this pre-arranged trading plan was adopted by the reporting person on March 13, 2026, and the Rule 10b5-1 checkbox was affirmatively marked.

What type of security did Karen Soares trade in the CLOV Form 4?

Karen Soares traded Class A Common Stock of Clover Health Investments, Corp. The Form 4 reports a single non-derivative transaction, identified with the code “S” for a sale, covering 51,700 shares at a weighted average price of $4.51 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soares Karen

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/20/2026		S		51,700(1)	D	$4.51(2)	1,505,522	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)